Abstracts Archive - Page 1598 of 2607 - ACR Meeting Abstracts

Abstract Number: 1772 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1390 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1277 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1270 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1012 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 569 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 476 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 454 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 180 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 47 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 3L • 2016 ACR/ARHP Annual Meeting
Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial
Jon T. Giles¹, Naveed Sattar², Sherine E. Gabriel³, Paul M. Ridker⁴, Steffen Gay⁵, Charles Warne⁶, David Musselman⁷, Laura Brockwell⁶, Emma Shittu⁶, Micki Klearman⁷ and Thomas Fleming⁸, ¹Columbia University, College of Physicians and Surgeons, New York, NY, ²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, MA, ⁵University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸University of Washington, Department of Biostatistics, Seattle, WA
Background/Purpose: Treatment of rheumatoid arthritis (RA) with tocilizumab (TCZ), a humanized monoclonal antibody directed against the IL-6 receptor, is associated with clinical efficacy and marked…
Abstract Number: 4L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, William Barchuk⁵, Xie Xu⁵ and Elizabeth C. Hsia⁴, ¹Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: To evaluate the efficacy, safety, and tolerability of guselkumab (GUS), a fully human monoclonal antibody against the p19 subunit of IL-23, in patients (pts)…
Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].